BlackRock
SKYE icon

BlackRock’s Skye Bioscience SKYE Stock Holding History

BlackRock’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$176K Buy
286,131
+4,290
+2% +$3.5K ﹤0.01% 4807
2025
Q4 		$211K Buy
281,841
+1,980
+0.7% +$2.89K ﹤0.01% 4710
2025
Q3 		$1.1M Sell
279,861
-132,756
-32% -$501K ﹤0.01% 4266
2025
Q2 		$1.72M Sell
412,617
-789,075
-66% -$1.63M ﹤0.01% 4104
2025
Q1 		$1.91M Sell
1,201,692
-18,494
-2% -$50.5K ﹤0.01% 4010
2024
Q4 		$3.45M Buy
1,220,186
+26,671
+2% +$111K ﹤0.01% 3864
2024
Q3 		$4.67M Buy
1,193,515
+74,748
+7% +$419K ﹤0.01% 3722
2024
Q2 		$8.96M Buy
+1,118,767
New +$13.3M ﹤0.01% 3437

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock's SKYE Position: Q1 2026 in Review

BlackRock increased its Skye Bioscience (SKYE) stake by 1.5% in Q1 2026, buying an estimated $3.5K and bringing the position to 286,131 shares worth $176K. The position accounts for ﹤0.01% of the portfolio, ranked #4807.

BlackRock first reported a position in SKYE in Q2 2024 and has held it in 8 quarters since. The position peaked at $8.96M in Q2 2024. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • BlackRock held 286,131 shares of Skye Bioscience worth $176K as of Q1 2026.
  • BlackRock bought 4,290 Skye Bioscience shares in Q1 2026, an estimated $3.5K.
  • Skye Bioscience made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #4807 holding.
  • BlackRock first reported a position in Skye Bioscience in Q2 2024 and has held it in 8 quarters since.
  • BlackRock's Skye Bioscience position peaked at $8.96M in Q2 2024.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.